SCHEMBL20223530

SCHEMBL20223530

CC(C)C(=O)CCOCCNC(=O)CC(=O)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.34
CA12 O43570 4/20 0.33
CA1 P00915 4/20 0.33
CA2 P00918 4/20 0.33
CA4 P22748 4/20 0.33
CA9 Q16790 4/20 0.33
CA14 Q9ULX7 4/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.31
HPGD P15428 2/20 0.31
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26412077 0.91 MEN1 (0.47) KMT2AMEN1ALDH1A1TSHRCA12
SCHEMBL23386933 0.89 MEN1 (0.50) KMT2AMEN1ALDH1A1TSHRCA12
SCHEMBL25812337 0.89 MEN1 (0.46) KMT2AMEN1ALDH1A1TSHRCA12
SCHEMBL27423424 0.88 MEN1 (0.42) KMT2AMEN1ALDH1A1TSHRCA12
SCHEMBL20226534 0.88 MEN1 (0.49) KMT2AMEN1ALDH1A1TSHRCA12
SCHEMBL25560484 0.86 MEN1 (0.47) KMT2AMEN1ALDH1A1TSHRCA12
SCHEMBL24812855 0.86 KMT2A (0.43) KMT2AMEN1ALDH1A1TSHRCA12
SCHEMBL24700122 0.86 CASP2 (0.44) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2
SCHEMBL17123136 0.85 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1TSHRCA12
SCHEMBL19491599 0.85 MEN1 (0.46) KMT2AMEN1ALDH1A1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240218011-A1 GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF FIREFLY BIO, INC. 2024-07-04 US disclosed
US-11760775-B2 Steroids and protein-conjugates thereof REGENERON PHARMACEUTICALS, INC. 2023-09-19 US disclosed
US-20180155389-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. 2018-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240218011-A1 GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF NR3C1, NR3C2, MC2R KMT2A 4239/4885MEN1 4297/4885ALDH1A1 3778/4885
US-20180155389-A1 STEROIDS AND PROTEIN-CONJUGATES THEREOF SERPINA6, NR3C1, NR3C2 KMT2A 4571/4885MEN1 2876/4885ALDH1A1 4143/4885
US-11760775-B2 Steroids and protein-conjugates thereof SERPINA6, NR3C1, NR3C2 KMT2A 4548/4885MEN1 2791/4885ALDH1A1 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.